Logo image of BRTX

BIORESTORATIVE THERAPIES INC (BRTX) Stock Fundamental Analysis

NASDAQ:BRTX - Nasdaq - US0906556065 - Common Stock - Currency: USD

1.8  -0.16 (-8.16%)

After market: 1.75 -0.05 (-2.78%)

Fundamental Rating

3

Taking everything into account, BRTX scores 3 out of 10 in our fundamental rating. BRTX was compared to 572 industry peers in the Biotechnology industry. The financial health of BRTX is average, but there are quite some concerns on its profitability. BRTX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year BRTX has reported negative net income.
BRTX had a negative operating cash flow in the past year.
BRTX had negative earnings in each of the past 5 years.
BRTX had a negative operating cash flow in each of the past 5 years.
BRTX Yearly Net Income VS EBIT VS OCF VS FCFBRTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M

1.2 Ratios

Looking at the Return On Assets, with a value of -42.34%, BRTX is in line with its industry, outperforming 53.11% of the companies in the same industry.
The Return On Equity of BRTX (-61.76%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -42.34%
ROE -61.76%
ROIC N/A
ROA(3y)-130.82%
ROA(5y)-329.63%
ROE(3y)-142.01%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BRTX Yearly ROA, ROE, ROICBRTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500 -500 -1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BRTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BRTX Yearly Profit, Operating, Gross MarginsBRTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20K -40K -60K -80K

More info and screens

5

2. Health

2.1 Basic Checks

BRTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
BRTX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, BRTX has more shares outstanding
There is no outstanding debt for BRTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BRTX Yearly Shares OutstandingBRTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M
BRTX Yearly Total Debt VS Total AssetsBRTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

2.2 Solvency

BRTX has an Altman-Z score of -15.14. This is a bad value and indicates that BRTX is not financially healthy and even has some risk of bankruptcy.
BRTX has a worse Altman-Z score (-15.14) than 82.42% of its industry peers.
BRTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -15.14
ROIC/WACCN/A
WACC9.44%
BRTX Yearly LT Debt VS Equity VS FCFBRTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M

2.3 Liquidity

BRTX has a Current Ratio of 2.95. This indicates that BRTX is financially healthy and has no problem in meeting its short term obligations.
BRTX has a worse Current ratio (2.95) than 66.07% of its industry peers.
BRTX has a Quick Ratio of 2.95. This indicates that BRTX is financially healthy and has no problem in meeting its short term obligations.
BRTX has a Quick ratio of 2.95. This is in the lower half of the industry: BRTX underperforms 63.59% of its industry peers.
Industry RankSector Rank
Current Ratio 2.95
Quick Ratio 2.95
BRTX Yearly Current Assets VS Current LiabilitesBRTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

More info and screens

6

3. Growth

3.1 Past

BRTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 62.95%, which is quite impressive.
The Revenue has grown by 214.17% in the past year. This is a very strong growth!
The Revenue has been growing slightly by 5.80% on average over the past years.
EPS 1Y (TTM)62.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.38%
Revenue 1Y (TTM)214.17%
Revenue growth 3Y22.15%
Revenue growth 5Y5.8%
Sales Q2Q%662.21%

3.2 Future

The Earnings Per Share is expected to grow by 28.95% on average over the next years. This is a very strong growth
BRTX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 263.46% yearly.
EPS Next Y64.36%
EPS Next 2Y25.69%
EPS Next 3Y19.62%
EPS Next 5Y28.95%
Revenue Next Year486.62%
Revenue Next 2Y327.98%
Revenue Next 3Y180.25%
Revenue Next 5Y263.46%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BRTX Yearly Revenue VS EstimatesBRTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M
BRTX Yearly EPS VS EstimatesBRTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BRTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BRTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BRTX Price Earnings VS Forward Price EarningsBRTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BRTX Per share dataBRTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 -1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as BRTX's earnings are expected to grow with 19.62% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.69%
EPS Next 3Y19.62%

More info and screens

0

5. Dividend

5.1 Amount

BRTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIORESTORATIVE THERAPIES INC

NASDAQ:BRTX (2/21/2025, 8:04:17 PM)

After market: 1.75 -0.05 (-2.78%)

1.8

-0.16 (-8.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)03-31 2025-03-31/amc
Inst Owners13.91%
Inst Owner Change-95.66%
Ins Owners27.05%
Ins Owner Change0%
Market Cap12.46M
Analysts82.5
Price Target13.26 (636.67%)
Short Float %4.67%
Short Ratio2.76
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)40.96%
Min EPS beat(2)12.47%
Max EPS beat(2)69.45%
EPS beat(4)4
Avg EPS beat(4)34.68%
Min EPS beat(4)12.47%
Max EPS beat(4)69.45%
EPS beat(8)7
Avg EPS beat(8)22.62%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)223.62%
Min Revenue beat(2)-34.45%
Max Revenue beat(2)481.7%
Revenue beat(4)3
Avg Revenue beat(4)150.05%
Min Revenue beat(4)-34.45%
Max Revenue beat(4)481.7%
Revenue beat(8)6
Avg Revenue beat(8)103.46%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)28.57%
EPS NY rev (1m)0%
EPS NY rev (3m)22.88%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-16.62%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 33.04
P/FCF N/A
P/OCF N/A
P/B 1.25
P/tB 1.33
EV/EBITDA N/A
EPS(TTM)-1.53
EYN/A
EPS(NY)-1.48
Fwd EYN/A
FCF(TTM)-1.13
FCFYN/A
OCF(TTM)-1.11
OCFYN/A
SpS0.05
BVpS1.44
TBVpS1.35
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -42.34%
ROE -61.76%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-130.82%
ROA(5y)-329.63%
ROE(3y)-142.01%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 89.36%
Cap/Sales 43.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.95
Quick Ratio 2.95
Altman-Z -15.14
F-Score4
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)167.73%
Cap/Depr(5y)N/A
Cap/Sales(3y)181.33%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)62.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.38%
EPS Next Y64.36%
EPS Next 2Y25.69%
EPS Next 3Y19.62%
EPS Next 5Y28.95%
Revenue 1Y (TTM)214.17%
Revenue growth 3Y22.15%
Revenue growth 5Y5.8%
Sales Q2Q%662.21%
Revenue Next Year486.62%
Revenue Next 2Y327.98%
Revenue Next 3Y180.25%
Revenue Next 5Y263.46%
EBIT growth 1Y27.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-37.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-40.42%
OCF growth 3YN/A
OCF growth 5YN/A